Analysts have revised their earnings per share (EPS) estimates for several publicly traded companies, providing insights into stock performance and market expectations. These updates reflect the latest evaluations from various financial analysts and indicate shifting market sentiments.
Key Stock Updates
For PowerFleet (NASDAQ:AIOT), analysts at Barrington Research reaffirmed their **outperform** rating, maintaining a target price of **$15.00**. Similarly, Barrett Business Services (NASDAQ:BBSI) received an **outperform** rating from Barrington Research, which has set a target price of **$46.00**.
In another notable update, Carriage Services (NYSE:CSV) also retained its **outperform** rating with a target price of **$60.00**, according to Barrington Research.
On the other hand, Domino’s Pizza (NASDAQ:DPZ) faced a downgrade, as analysts at TD Cowen reiterated a **hold** rating, reducing the target price from **$500.00** to **$460.00**. This adjustment reflects changing expectations for the popular pizza chain.
Additional Ratings and Price Targets
Further updates include GH Research (NASDAQ:GHRS), which saw its **buy** rating reaffirmed by Needham & Company LLC, setting a price target of **$19.00**. Heritage Commerce (NASDAQ:HTBK) continues to hold an **equal weight** rating as per Stephens, indicating a stable outlook.
In the biotech sector, Humacyte (NASDAQ:HUMA) had its **buy** rating reaffirmed by D. Boral Capital, with a target price of **$25.00**. Meanwhile, Janus Henderson Group (NYSE:JHG) had its **neutral** rating reissued by Bank of America Corporation, with a price target adjustment from **$54.00** to **$49.00**.
Other companies receiving attention include Life360 (NASDAQ:LIF), which maintained its **market perform** rating according to Citizens Jmp, and Microsoft (NASDAQ:MSFT), which continues to hold a **buy** rating from the Royal Bank of Canada.
Analysts at D. Boral Capital have also reaffirmed their **buy** ratings for NRx Pharmaceuticals (NASDAQ:NRXP) and Urogen Pharma (NASDAQ:URGN), with target prices set at **$34.00** and **$33.00**, respectively.
Finally, U.S. Physical Therapy (NYSE:USPH) retains an **outperform** rating with a target price of **$103.00**, while DENTSPLY SIRONA (NASDAQ:XRAY) also holds an **outperform** rating with a price target established at **$14.00**.
These updates from analysts provide investors with critical insights into expected performance and potential investment opportunities across various sectors. Staying informed on these ratings can help stakeholders make more strategic decisions in a constantly evolving market landscape.
